Lisanti Capital Growth LLC Grows Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Lisanti Capital Growth LLC grew its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 80.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,910 shares of the specialty pharmaceutical company’s stock after buying an additional 11,990 shares during the period. Lisanti Capital Growth LLC owned approximately 0.13% of ANI Pharmaceuticals worth $1,488,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. State Street Corp grew its stake in ANI Pharmaceuticals by 9.1% in the 3rd quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company’s stock worth $41,991,000 after buying an additional 58,698 shares in the last quarter. Pacer Advisors Inc. grew its stake in ANI Pharmaceuticals by 23,259.8% in the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock worth $33,907,000 after buying an additional 565,910 shares in the last quarter. JPMorgan Chase & Co. grew its stake in ANI Pharmaceuticals by 159.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock worth $33,101,000 after buying an additional 340,854 shares in the last quarter. Global Alpha Capital Management Ltd. boosted its stake in shares of ANI Pharmaceuticals by 1.8% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock valued at $32,005,000 after purchasing an additional 9,500 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of ANI Pharmaceuticals by 4.2% in the 3rd quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock valued at $25,373,000 after purchasing an additional 17,314 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the transaction, the senior vice president now directly owns 49,059 shares in the company, valued at approximately $2,943,540. This represents a 2.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the transaction, the chief financial officer now owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,300 shares of company stock valued at $584,009 in the last quarter. Company insiders own 12.70% of the company’s stock.

Wall Street Analyst Weigh In

ANIP has been the subject of a number of research reports. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. StockNews.com cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective for the company. Guggenheim upped their price objective on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $79.00.

ANI Pharmaceuticals Trading Up 2.3 %

Shares of ANIP opened at $61.05 on Friday. The stock has a market capitalization of $1.28 billion, a P/E ratio of -111.00 and a beta of 0.74. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a fifty day simple moving average of $57.53 and a two-hundred day simple moving average of $58.11. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $70.81.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.